These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 9539301

  • 1. Effect of growth hormone therapy in children with achondroplasia: growth pattern, hypothalamic-pituitary function, and genotype.
    Tanaka H, Kubo T, Yamate T, Ono T, Kanzaki S, Seino Y.
    Eur J Endocrinol; 1998 Mar; 138(3):275-80. PubMed ID: 9539301
    [Abstract] [Full Text] [Related]

  • 2. Growth hormone therapy in achondroplasia.
    Seino Y, Yamanaka Y, Shinohara M, Ikegami S, Koike M, Miyazawa M, Inoue M, Moriwake T, Tanaka H.
    Horm Res; 2000 Mar; 53 Suppl 3():53-6. PubMed ID: 10971105
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Molecular defects in achondroplasia and the effects of growth hormone treatment.
    Seino Y, Moriwake T, Tanaka H, Inoue M, Kanzaki S, Tanaka T, Matsuo N, Niimi H.
    Acta Paediatr Suppl; 1999 Feb; 88(428):118-20. PubMed ID: 10102070
    [Abstract] [Full Text] [Related]

  • 7. Growth and growth hormone therapy in children with achondroplasia: a two-year experience.
    Stamoyannou L, Karachaliou F, Neou P, Papataxiarchou K, Pistevos G, Bartsocas CS.
    Am J Med Genet; 1997 Oct 03; 72(1):71-6. PubMed ID: 9295079
    [Abstract] [Full Text] [Related]

  • 8. [Mutations in the Fibroblast Growth Factor Receptor 3 gene (FGFR3) in Chilean patients with idiopathic short stature, hypochondroplasia and achondroplasia].
    Mancilla EE, Poggi H, Repetto G, García C, Foradori A, Cattani A.
    Rev Med Chil; 2003 Dec 03; 131(12):1405-10. PubMed ID: 15022403
    [Abstract] [Full Text] [Related]

  • 9. Growth hormone treatment in 35 prepubertal children with achondroplasia: a five-year dose-response trial.
    Hertel NT, Eklöf O, Ivarsson S, Aronson S, Westphal O, Sipilä I, Kaitila I, Bland J, Veimo D, Müller J, Mohnike K, Neumeyer L, Ritzen M, Hagenäs L.
    Acta Paediatr; 2005 Oct 03; 94(10):1402-10. PubMed ID: 16299871
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Skeletal dysplasia, growth hormone treatment and body proportion: comparison with other syndromic and non-syndromic short children.
    Hagenäs L, Hertel T.
    Horm Res; 2003 Oct 03; 60 Suppl 3():65-70. PubMed ID: 14671400
    [Abstract] [Full Text] [Related]

  • 12. Favorable Growth Hormone Treatment Response in a Young Boy with Achondroplasia.
    Krstevska-Konstantinova M, Stamatova A, Gucev Z.
    Med Arch; 2016 Apr 03; 70(2):148-50. PubMed ID: 27147792
    [Abstract] [Full Text] [Related]

  • 13. Genotype phenotype correlation in achondroplasia and hypochondroplasia.
    Matsui Y, Yasui N, Kimura T, Tsumaki N, Kawabata H, Ochi T.
    J Bone Joint Surg Br; 1998 Nov 03; 80(6):1052-6. PubMed ID: 9853502
    [Abstract] [Full Text] [Related]

  • 14. Growth hormone therapy in achondroplasia.
    Nishi Y, Kajiyama M, Miyagawa S, Fujiwara M, Hamamoto K.
    Acta Endocrinol (Copenh); 1993 May 03; 128(5):394-6. PubMed ID: 8317186
    [Abstract] [Full Text] [Related]

  • 15. Present status of the use of growth hormone in short children with bone diseases (diseases of the skeleton).
    Kanaka-Gantenbein C.
    J Pediatr Endocrinol Metab; 2001 Jan 03; 14(1):17-26. PubMed ID: 11220700
    [Abstract] [Full Text] [Related]

  • 16. Short-term recombinant human growth hormone treatment increases growth rate in achondroplasia.
    Shohat M, Tick D, Barakat S, Bu X, Melmed S, Rimoin DL.
    J Clin Endocrinol Metab; 1996 Nov 03; 81(11):4033-7. PubMed ID: 8923856
    [Abstract] [Full Text] [Related]

  • 17. Recombinant human growth hormone plus recombinant human insulin-like growth factor-1 coadministration therapy in short children with low insulin-like growth factor-1 and growth hormone sufficiency: results from a randomized, multicenter, open-label, parallel-group, active treatment-controlled trial.
    Backeljauw PF, Miller BS, Dutailly P, Houchard A, Lawson E, Hale DE, Reiner B, Sperling MA, MS316 Study Group.
    Horm Res Paediatr; 2015 Nov 03; 83(4):268-79. PubMed ID: 25765099
    [Abstract] [Full Text] [Related]

  • 18. Genotype and phenotype in hypochondroplasia.
    Ramaswami U, Rumsby G, Hindmarsh PC, Brook CG.
    J Pediatr; 1998 Jul 03; 133(1):99-102. PubMed ID: 9672519
    [Abstract] [Full Text] [Related]

  • 19. Clinical outcomes and medical management of achondroplasia in Japanese children: A retrospective medical record review of clinical data.
    Saitou H, Kitaoka T, Kubota T, Kanno J, Mochizuki H, Michigami T, Hasegawa K, Fujiwara I, Hamajima T, Harada D, Seki Y, Nagasaki K, Dateki S, Namba N, Tokuoka H, Pimenta JM, Cohen S, Ozono K.
    Am J Med Genet A; 2024 Aug 03; 194(8):e63612. PubMed ID: 38554024
    [Abstract] [Full Text] [Related]

  • 20. Final adult height in long-term growth hormone-treated achondroplasia patients.
    Harada D, Namba N, Hanioka Y, Ueyama K, Sakamoto N, Nakano Y, Izui M, Nagamatsu Y, Kashiwagi H, Yamamuro M, Ishiura Y, Ogitani A, Seino Y.
    Eur J Pediatr; 2017 Jul 03; 176(7):873-879. PubMed ID: 28501952
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.